Lauren Doyle Strauss1, Marianna Shnayderman Yugrakh2, Kayla E Kaplan3, Mia T Minen4,5. 1. Department of Neurology, Wake Forest Baptist Medical Center, Brenner Children's Hospital, Winston-Salem, NC, USA. 2. Department of Neurology, Columbia University Medical Center, New York, NY, USA. 3. Barnard College, Columbia University, New York, NY, USA. 4. Department of Neurology, NYU Langone Health, New York, NY, USA. 5. Department of Population Health, NYU Langone Health, New York, NY, USA.
Abstract
BACKGROUND: Infusion therapy refers to the intravenous administration of medicines and fluids for the treatment of status migrainosus, severe persistent headaches, or chronic headache. Headache practices and centers offer this treatment for patients as an alternative to the emergency department (ED) setting. However, little information is available in the literature on understanding the operations of an infusion center. OBJECTIVE: We sought to survey the Inpatient Headache & Emergency Medicine specialty section and the Academic Program Directors listserv of the American Headache Society (AHS) to better understand current practices. METHODS: A survey was advertised and distributed to the listservs of both the Inpatient Headache & Emergency Medicine specialty section and the Academic Program Directors, which combined included both academic and private practices. In addition, the survey was available on laptops at related events at an annual AHS meeting in Scottsdale. RESULTS: Of the 127 members of the combined group of both listservs, 50 responded with an overall survey response rate of 39%. Ten out of fifty were from programs with more than one responder completing the survey, leaving 40 unique headache programs. Academic programs made up the majority of programs (85%, 34/40). The total of 40 participating programs is comparable with the 47 academic headache programs listed on the American Migraine Foundation website at the time of the survey. Of the academic programs surveyed, most were hospital based (n = 23) compared with a satellite location (n = 11). Of all programs surveyed, 68% (27/40) offered infusion therapy. Of those that did not have an infusion practice (n = 13), the most common reason cited was insufficient staffing (n = 8). Key highlights of the survey included the following: The majority of programs offering infusions obtain prior authorization before scheduling (70%, 19/27) and offer patient availability 5 days/week (78%, 21/27) typically only during business hours (81%, 22/27). Programs reported that they typically give three to four medications during each infusion session (72%, 18/25). Treatment paradigms varied between programs. Programs surveyed were concentrated in the Northeast and Midwest regions of the United States. CONCLUSION: The limited number of headache infusion centers overall may contribute to the limited ability of headache infusion centers to prevent ED migraine visits. Headache patients can have unpredictable headache onset, and most of the infusion practices surveyed appeared to adapt to this by offering infusions most days during a work week. However, this need for multiple days per week may also explain the most common reason for not having an infusion practice, which is insufficient staffing. Various treatment paradigms are implemented by different practitioners, and future studies will have to focus on investigation of best practice.
BACKGROUND: Infusion therapy refers to the intravenous administration of medicines and fluids for the treatment of status migrainosus, severe persistent headaches, or chronic headache. Headache practices and centers offer this treatment for patients as an alternative to the emergency department (ED) setting. However, little information is available in the literature on understanding the operations of an infusion center. OBJECTIVE: We sought to survey the Inpatient Headache & Emergency Medicine specialty section and the Academic Program Directors listserv of the American Headache Society (AHS) to better understand current practices. METHODS: A survey was advertised and distributed to the listservs of both the Inpatient Headache & Emergency Medicine specialty section and the Academic Program Directors, which combined included both academic and private practices. In addition, the survey was available on laptops at related events at an annual AHS meeting in Scottsdale. RESULTS: Of the 127 members of the combined group of both listservs, 50 responded with an overall survey response rate of 39%. Ten out of fifty were from programs with more than one responder completing the survey, leaving 40 unique headache programs. Academic programs made up the majority of programs (85%, 34/40). The total of 40 participating programs is comparable with the 47 academic headache programs listed on the American Migraine Foundation website at the time of the survey. Of the academic programs surveyed, most were hospital based (n = 23) compared with a satellite location (n = 11). Of all programs surveyed, 68% (27/40) offered infusion therapy. Of those that did not have an infusion practice (n = 13), the most common reason cited was insufficient staffing (n = 8). Key highlights of the survey included the following: The majority of programs offering infusions obtain prior authorization before scheduling (70%, 19/27) and offer patient availability 5 days/week (78%, 21/27) typically only during business hours (81%, 22/27). Programs reported that they typically give three to four medications during each infusion session (72%, 18/25). Treatment paradigms varied between programs. Programs surveyed were concentrated in the Northeast and Midwest regions of the United States. CONCLUSION: The limited number of headache infusion centers overall may contribute to the limited ability of headache infusion centers to prevent ED migraine visits. Headache patients can have unpredictable headache onset, and most of the infusion practices surveyed appeared to adapt to this by offering infusions most days during a work week. However, this need for multiple days per week may also explain the most common reason for not having an infusion practice, which is insufficient staffing. Various treatment paradigms are implemented by different practitioners, and future studies will have to focus on investigation of best practice.
Authors: Benjamin W Friedman; Leonid Garber; Andrew Yoon; Clemencia Solorzano; Andrew Wollowitz; David Esses; Polly E Bijur; E John Gallagher Journal: Neurology Date: 2014-02-12 Impact factor: 9.910
Authors: Frederick G Freitag; Al Lake; Richard Lipton; Roger Cady; Seymour Diamond; Stephen Silberstein Journal: Headache Date: 2004-04 Impact factor: 5.887
Authors: Benjamin W Friedman; Eddie Irizarry; Clemencia Solorzano; Alexander Latev; Karolyn Rosa; Eleftheria Zias; David R Vinson; Polly E Bijur; E John Gallagher Journal: Neurology Date: 2017-10-18 Impact factor: 9.910
Authors: Christina L Szperka; Jessica Ailani; Rebecca Barmherzig; Brad C Klein; Mia T Minen; Rashmi B Halker Singh; Robert E Shapiro Journal: Headache Date: 2020-04-03 Impact factor: 5.311
Authors: Mia T Minen; Dennique Khanns; Jenny Guiracocha; Annika Ehrlich; Fawad A Khan; Ashhar S Ali; Marius Birlea; Niranjan N Singh; Addie Peretz; I V Larry Charleston Journal: BMC Health Serv Res Date: 2022-02-08 Impact factor: 2.655